Jump to content


ameliaeve030

Member Since 25 Sep 2021
Offline Last Active Sep 25 2021 10:42 AM
-----

Community Stats


  • Group User
  • Active Posts 0
  • Profile Views 822
  • Time Online8m 41s
  • Member Title Newbie
  • Age 24 years old
  • Birthday November 16, 1999
  • Gender
    Male Male
  • Location
    USA
  • Interests
    Pharmacology: Pharmacodynamics: Mechanism of action: Ibrutinib is a potent, small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue (Cys-481) in the BTK active site, leading to sustained inhibition of BTK enzymatic activity. BTK, a member of the Tec kinase family, is an important signalling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. The BCR pathway is implicated in the pathogenesis of several B-cell malignancies, including MCL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and CLL. BTK's pivotal role in signalling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis and adhesion. Preclinical studies have shown that ibrutinib effectively inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.

Contact Information


Game Activity

  • Photo
    ameliaeve030 does not have any recent game activity.
    Recent game activity may take a few minutes to refresh on this page.

Friends

ameliaeve030 hasn't added any friends yet.

Latest Visitors

No latest visitors to show